Cipla Ltd.
-
NSE: CIPLA
-
BSE: 500087
-
Q
-
V
-
T
Quality Score
High Financial StrengthValuation Score
Mid ValuationTechnical Score
Technically NeutralBroker average target upside %
14.00 %
Above industry Median
TTM PE Ratio
27.80
Above industry Median
Price to Book Ratio
3.30
Below industry Median
Operating Revenues Qtr Cr
5739.30 Cr
High in industry
Net Profit Qtr Cr
521.50 Cr
High in industry
RSI
67.30
RSI is mid-range
MFI
51.20
MFI is mid-range
MACD
10.70
MACD above Signal and Center
MACD Signal Line
7.70
MACD above Signal and Center
30Day SMA Rs
929.40 Rs
Price above SMA 929.43
50Day SMA Rs
914.60 Rs
Price above SMA 914.58
100Day SMA Rs
956.20 Rs
price crossed below SMA100 today
200Day SMA Rs
1024.80 Rs
Price below SMA-200
Promoter holding %
33.55
Promoter holding decreased by 0.0600%.
FII holding current Qtr %
27.42
FII holdings fell by 0.97%
MF holding current Qtr %
15.00
MF holdings rise by 0.91%
Institutions holding %
49.51
No change in Institutions holding
Broker Average Rating
4.25
Broker Average Rating
Broker Covering stock
11.00
11 Broker Covering stock
Broker 1Year total
33.00
33 Broker 1Year total
Broker 6M Reco downgrade
1.00
1 Broker 6M Reco downgrade
Broker 6M Reco upgrade
2.00
2 Broker 6M Reco upgrade
Broker 6M Target downgrade
12.00
12 Broker 6M Target downgrade
Broker 6M Target upgrade
2.00
2 Broker 6M Target upgrade
Momentum score
49.78
Technically Neutral
Valuation score
31.67
Mid Valuation
Quality score
84.03
High Financial Strength
-
- 2023-05-31T15:53:56+00:00
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 14th March 2023, this is to inform you that the proposed sale of stake held in Cipla Quality Chemical Industries Limited(CQCIL), step-down subsidiary of the Company in Uganda, is expected to be completed on or before 31st July 2023. This timeline is subject to receipt of regulatory approvals and satisfaction of conditions as agreed in the Share Purchase Agreement ('SPA') signed between the parties and may be further extended as mutually agreed between the parties.
Read More -
- 2023-05-30T14:07:39+00:00
CIPLA LTD. - 500087 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations 2015, please find enclosed the Annual Secretarial Compliance Report for the financial year 2022-23 issued by BNP & Associates, Practising Company Secretaries.
Read More -
- 2023-05-29T14:54:31+00:00
CIPLA LTD. - 500087 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI Listing Regulations, we would like to inform you that Registrar and Transfer Agent of Company M/s. KFin Technologies Limited has received intimation for loss of share certificate and request for issuance of duplicate share certificate from the following shareholder
Read More -
- 2023-05-26T12:03:50+00:00
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 26th May 2023 has allotted 67,306 fully paid-up equity shares of INR 2 each, pursuant to exercise of employee stock options under the Employee Stock Option Scheme 2013-A of the Company. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to INR 1,61,44,48,872 comprising of 80,72,24,436 equity shares of face value INR 2 each.
Read More -
- 2023-05-16T10:21:53+00:00
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
We are enclosing herewith copy of the transcript of the Company's Q4 FY23 earnings conference call dated 12th May 2023. The transcript is also available on the Company's website i.e. https://www.cipla.com/sites/default/files/Transcript-Q4FY23-Audited-Financial-Results-31March2023.pdf.
Read More -
- 2023-05-15T18:24:52+00:00
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
In compliance with the provisions of Regulation 30 of the SEBI Listing Regulations, we hereby notify that the Company has entered into a binding term sheet to sell its entire stake of 51% held in Saba Investment Limited, UAE ('Saba') to Shibam Group Holding Limited, UAE. Consequent to the sale, upon execution of the transaction, Saba and its subsidiaries viz Cipla Middle East Pharmaceuticals FZ LLC, UAE ('CME') and Cipla Medica Pharmaceutical and Chemical Industries Limited, Yemen ('Cipla Medica'), will cease to be subsidiaries of the Company.
Read More -
- 2023-05-15T12:18:15+00:00
CIPLA LTD. - 500087 - Machine-Readable Version Of Audited Financial Results For The Quarter And Year Ended 31St March 2023
Please note that we have submitted the audited financial results (standalone and consolidated) for the quarter and financial year ended 31st March 2023 along with the Auditor's Report with the unmodified opinion within the stipulated time on 12th May 2023 and the same was duly taken on record by the exchanges. However, we have realized that the submission was not in the machine-readable form, therefore we enclosing the identical submission in the machine-readable form.
Read More -
- 2023-05-12T16:17:44+00:00
CIPLA LTD. - 500087 - Details Of Related Party Transactions For The Half-Year Ended 31St March 2023
Details of Related Party Transactions for the half-year ended March 31, 2023.
Read More -
- 2023-05-12T14:52:36+00:00
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the audio recording of the earnings conference call for Q4 FY 23 held today is available on the Company's website at https://www.cipla.com/audio/9060
Read More -
- 2023-05-12T14:22:35+00:00
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Resignation of Director
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we hereby notify that Dr. Peter Mugyenyi, Independent Director of the Company has vide letter dated 12th May 2023 resigned from the position of Independent Director of the Company with effect from 13th May 2023.
Read More -
- 2023-05-12T13:35:24+00:00
CIPLA LTD. - 500087 - Record Date For Payment Of Final Dividend For The FY 2022-23.
Pursuant to Regulation 42 of the SEBI LODR Regulations, the Company has fixed the ''Record Date'' for payment of final dividend.
Read More -
- 2023-05-12T13:20:33+00:00
CIPLA LTD. - 500087 - Grants In Terms Of The Employee Stock Option Scheme 2013-A ('ESOS 2013-A') And The Cipla Employee Stock Appreciation Rights Scheme 2021 ('ESAR 2021')
This is to inform you that the Company has made the following grants in terms of the Employee Stock Option Scheme 2013-A ('ESOS 2013-A') and the Cipla Employee Stock Appreciation Rights Scheme 2021 ('ESAR 2021') under SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021
Read More -
- 2023-05-12T13:19:20+00:00
Cipla Results Earnings Call for Q4FY23
Conference Call with Cipla Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
Read More -
- 2023-05-12T10:05:47+00:00
Q4FY23 Quarterly & FY23 Annual Result Announced for Cipla Ltd.
Pharmaceuticals company Cipla announced Q4FY23 & FY23 results: Q4FY23: Income from Operations: Rs 5,739 crore, up 9% YoY EBITDA Margin: Rs 1,174 crore Adjusted PAT: Rs 708 crore FY23: Income from Operations: Rs 22,753 crore, up 5% YoY EBITDA Margin: Rs 5,027 crore Adjusted PAT: Rs 2,984 crore “I am pleased to share that we continue to make significant progress across our focused markets. In FY23, we recorded the highest-ever revenue with EBITDA crossing Rs 5,000 crore for the first time. Our One-India business continued the double-digit trajectory growing at 13% ex-Covid during the year led by branded prescription and sustained growth across our acute and chronic therapies. Our continued focus on the differentiated portfolio has strengthened our US business which posted the highest-ever quarterly revenue at USD 204 million and USD 733 million for FY23. Adjusting for covid, our core operating profitability continues to be strong at ~23% expanding by 100 bps over last year. We are excited for the upcoming year, where we look forward to deepening our leadership in branded markets and expanding our differentiated pipeline in the US.” said Umang Vohra, MD and Global CEO, Cipla. Result PDF
Read More -
- 2023-05-12T09:58:23+00:00
CIPLA LTD. - 500087 - Board Meeting Outcome for Board Meeting Outcome For Closure Of Board Meeting.
In furtherance to our intimation dated 12th May 2023 under Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that the meeting of the Board of Directors which commenced today at 11.45 a.m. (IST) has concluded at 3.15 p.m. (IST).
Read More -
- 2023-05-12T09:50:04+00:00
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing an extract of the Newspaper publications of consolidated audited financial results for the quarter and financial year ended 31st March, 2023.
Read More -
- 2023-05-12T09:40:36+00:00
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Press Release dated 12th May 2023.
Read More -
- 2023-05-12T09:38:47+00:00
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Investor Presentation dated 12th May 2023.
Read More -
- 2023-05-12T09:33:18+00:00
CIPLA LTD. - 500087 - Corporate Action-Board approves Dividend
Please find the attached intimation letter dated 12th May 2023.
Read More -
- 2023-05-12T09:29:23+00:00
CIPLA LTD. - 500087 - Financial Results And Declaration Of Dividend
Please find enclosed letter dated 12th May 2023.
Read More
| Ex-date | Dividend Amount | Dividend Type | Record Date |
|---|
Bonus History
Adani Ports & Special Economic Zone Ltd. has not announced any bonus since Jan 1, 2000.
Check out stocks with top dividendAdani Ports & Special Economic Zone Ltd. has split the face value 1 time since Sept. 23, 2010. Adani Ports & Special Economic Zone Ltd. had last split the face value of its shares from Rs 10 to Rs 2 in 2016.The share has been quoting on an ex-split basis from Sept. 23, 2010.
| Ex-date | Old FV | New FV | Record Date |
|---|---|---|---|
| Sept. 23, 2010 | 10 | FINAL | Sept. 24, 2010 |